ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC director James T. Parsons received a grant of stock options for 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.

The award was granted at no cost to Parsons and vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment. Following this grant, he holds options for 30,000 underlying common shares directly.

Insights

Equity compensation analyst

Routine director stock option grant with three-year vesting schedule.

Director James T. Parsons received options over 30,000 ONCOLYTICS BIOTECH INC common shares at an exercise price of $1.06, matching the Nasdaq Capital Market closing price on June 1, 2026. The grant is compensation-related, not an open-market purchase.

The options vest in three equal annual tranches beginning on June 1, 2027, requiring continued service for full vesting. Because this is a standard equity award and not a buy or sell transaction, it typically carries limited signaling value about the director’s view of the stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parsons James T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 30,000 shares (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Option grant size: 30,000 shares Exercise price: $1.06 per share Total options after grant: 30,000 options +2 more

5 metrics

Option grant size 30,000 shares Underlying common shares covered by new stock option grant

Exercise price $1.06 per share Equal to Nasdaq Capital Market closing price on June 1, 2026

Total options after grant 30,000 options Total derivative holdings following this transaction

Expiration date June 1, 2036 Stock option expiration

Vesting schedule Three equal annual installments First tranche vests June 1, 2027

Key Terms

Stock Option, exercise price, vests in three equal annual installments, Nasdaq Capital Market

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting"

Nasdaq Capital Market financial

"closing price of the Issuer's common stock on the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/03/2026 - 04:32 PM Accepted by SEC EDGAR 06/03/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What did ONCY director James T. Parsons receive in this Form 4 filing?

James T. Parsons received a grant of stock options for 30,000 ONCY common shares. The options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price if they vest.

What is the exercise price of James T. Parsons' ONCY stock options?

The exercise price is $1.06 per share, equal to the ONCY common stock closing price on the Nasdaq Capital Market on June 1, 2026. This means he can later buy shares at that price if the options vest.

When do James T. Parsons' ONCY stock options vest?

The 30,000 ONCY stock options vest in three equal annual installments starting June 1, 2027. Each year, one-third becomes exercisable, provided Parsons continues his service or employment through each vesting date.

Is James T. Parsons buying or selling ONCY shares in this Form 4?

He is not buying or selling ONCY shares on the market. The Form 4 reports a grant of stock options as compensation, giving him the right to acquire 30,000 common shares at $1.06 if the options vest and he exercises them.

How many ONCY shares are covered by James T. Parsons' new stock options?

The stock option grant covers 30,000 underlying ONCY common shares. After this award, his reported derivative holdings include options for those 30,000 shares, which may be exercised in the future if vesting conditions are met.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parsons James T.

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		30,000		(2)	06/01/2036	Common Shares	30,000	$0	30,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)